NCT01383109View on ClinicalTrials.gov

Human Mass Balance Study of Pyronaridine

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions
Malaria
Interventions
DRUG

14C-labeled Pyronaridine

Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).

Trial Locations (1)

4123

Covance Clinical Research Unit AG, Allschwil

All Listed Sponsors
collaborator

Shin Poong Pharmaceuticals

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT01383109 - Human Mass Balance Study of Pyronaridine | Biotech Hunter | Biotech Hunter